Simcere Pharmaceutical Group Ltd (2096)
Hong Kong Stock Exchange · Hong Kong · prices in HKD · close of 20 Oct 2026
Key indicators
| Last close | HKD 10.94 |
|---|---|
| 52-week range | 9.07 – 14.08 |
| Return, 1 month / 3 months | −2.9% / −16.9% |
| Return, 1 year / 3 years | −11.5% / +79.8% |
| Trend | Below its 200-day average |
| RSI (14) | 43 |
| Volatility (1 year) | 41.7% |
| Worst drawdown (1 year) | -32.6% |
| Average daily value traded | 60.18M HKD |
| Dividend yield | 1.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Simcere Pharmaceutical Group is a pharmaceutical company based in Nanjing, China. It develops, manufactures and markets medicines, with a focus on generic and branded prescription drugs. Its products serve hospitals and patients in China and cover areas such as central nervous system conditions, oncology and infectious disease. The company also works on innovative drug research alongside its established portfolio of treatments.
The shares are listed on the Hong Kong Stock Exchange in Hong Kong under the code 2096, and the price on this page is in Hong Kong dollars (HKD). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Simcere Pharmaceutical Group Ltd (2096) trades on the Hong Kong Stock Exchange in Hong Kong. It last closed at HKD 10.94 on 20 October 2026.
Its price-based Market X-Ray is 63 out of 100 (a fair price profile), ranking 723 of 2,611 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 11.5% and over the last three months it fell 16.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Hong Kong Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 69 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -5.3% | ||
| From 52-week high | -20.3% | ||
| Momentum | 42 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -16.9% | ||
| 6-month return | -19.0% | ||
| 12-month return, skipping the last month | -8.8% | ||
| Stability (higher is calmer) | 73 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 41.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -32.6% | ||
| Liquidity | 88 · Strong | Trades actively. | |
| Average daily value traded | 60.18M HKD | ||
| Zero-volume days | 0.0% | ||
| Income | 37 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.9% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Momentum: Lagging most stocks on this exchange.
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.4% |
|---|---|
| 1 month | −2.9% |
| 3 months | −16.9% |
| 6 months | −19.0% |
| 1 year | −11.5% |
| 3 years | +79.8% |
| 5 years | – |
Signals
| 50-day / 200-day average | 11.51 / 11.56 |
|---|---|
| Golden / death cross (60 days) | Death, 2 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.40 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 17 Jun 2026 | HKD 0.2069 |
| 18 Jun 2025 | HKD 0.1748 |
| 18 Jun 2024 | HKD 0.1757 |
| 19 Jun 2023 | HKD 0.1758 |
| 28 Jun 2022 | HKD 0.1757 |
| 29 Jun 2021 | HKD 0.1803 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Hong Kong Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.